<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="es">
	<id>https://crianzamutua.mx/api.php?action=feedcontributions&amp;feedformat=atom&amp;user=Mildred36T</id>
	<title>Crianza Mutua Alpha - Contribuciones del usuario [es]</title>
	<link rel="self" type="application/atom+xml" href="https://crianzamutua.mx/api.php?action=feedcontributions&amp;feedformat=atom&amp;user=Mildred36T"/>
	<link rel="alternate" type="text/html" href="https://crianzamutua.mx/Especial:Contribuciones/Mildred36T"/>
	<updated>2026-08-23T18:02:28Z</updated>
	<subtitle>Contribuciones del usuario</subtitle>
	<generator>MediaWiki 1.31.3</generator>
	<entry>
		<id>https://crianzamutua.mx/index.php?title=The_Remaining_Five_Trials_Included_1&amp;diff=49157</id>
		<title>The Remaining Five Trials Included 1</title>
		<link rel="alternate" type="text/html" href="https://crianzamutua.mx/index.php?title=The_Remaining_Five_Trials_Included_1&amp;diff=49157"/>
		<updated>2026-08-13T18:13:24Z</updated>

		<summary type="html">&lt;p&gt;Mildred36T: Página creada con «&amp;lt;br&amp;gt;42). There is insufficient evidence to evaluate the effect of DPP-4 inhibitors on at-risk patients. This Cochrane review included seven randomized controlled trials.1 B…»&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;br&amp;gt;42). There is insufficient evidence to evaluate the effect of DPP-4 inhibitors on at-risk patients. This Cochrane review included seven randomized controlled trials.1 Because of the limited number of participants-only 98 patients-and the lack of patient-oriented outcomes data from the two DPP-4 inhibitor trials, no conclusions could be drawn about that class of medication. The remaining five trials included 1,620 participants randomized to monotherapy with a GLP-1 receptor agonist. In a single randomized, double-blind, placebo-controlled trial, authors studied the effect of liraglutide (Victoza; a GLP-1 receptor agonist) in patients with prediabetes and obesity. After 160 weeks, [https://www.youtube.com/results?search_query=fewer%20patients fewer patients] treated with liraglutide developed diabetes than those treated with placebo (1.8% vs. 23). Because of limited data, no conclusions could be drawn regarding the effect of GLP-1 receptor agonists to decrease the risk of complications associated with diabetes. Patients receiving GLP-1 receptor agonists may experience serious adverse events including, but not limited to, myocardial infarction, cholelithiasis, cholecystitis, pancreatitis, intervertebral disk protrusion,  [http://www.tangjia7.com:8901/estellapritcha MedicGLP Website] abdominal and hiatal hernia, infection, and neoplasm.7 More individuals who received liraglutide had serious adverse events than those who received placebo (15.1% vs. 42). It is noteworthy that most of the data on GLP-1 receptor agonists came from the same large industry-sponsored study. Because of the small number of participants in the other GLP-1 receptor agonist studies,  [http://www.tangjia7.com:8901/estellapritcha/1982229/wiki/Your+Friendly+Guide+to+GLP-1+Weight+Loss%253A+what+Works%252C+what+Doesn%25E2%2580%2599t+and+What%25E2%2580%2599s+Next MedicGLP] no comparisons among the different agents and thus no conclusions regarding their relative benefit could be made.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Science continues to prove that the old adage &amp;quot;you are what you eat&amp;quot; is profoundly true. This is because you have trillions of microorganisms living in your gut, which are directly responsible for nearly every aspect of your health. These microbes make up what’s called your &amp;quot;gut microbiota.&amp;quot; They are especially influential in determining your likelihood of gaining excessive weight, becoming obese, and developing obesity-related diseases like diabetes, heart disease, and premature death. The gut microbiome (the expressed genes of your gut microbiota) plays a major  [https://crianzamutua.mx/Usuario:Mildred36T MedicGLP Website] role in your metabolism through energy production, storage, and expenditure. So, it’s no surprise that science has found a strong connection between gut microbiome imbalance and metabolic syndrome. Yikes! If you have the wrong mix of microbes, it could be making it tough for you to get your health on track! Did you know: Scientists can actually look at your gut microbiome composition and tell with 90% accuracy if you are obese or lean. That’s pretty impressive, isn’t it?&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;1. Unable to lose weight and keep it off? 2. Struggling to fight cravings? 3. Sick of starving yourself for weight loss? 4. Baffled as to why no diet seems to really work for you? Depending on the composition of your gut microbiome, your microbes can either boost your health or weigh you down (figuratively and literally). The good news is this: You have control over these little guys with every bite you eat. Diet has the power to change the landscape of your gut microbiome. So, if you’ve tried multiple diets and can’t seem to get the results you want,  [http://pcwang.vip:17608/cedricsexton1 MedicGLP Weight Management] it’s time to look into your gut microbiome.Will You Lose Weight Naturally on an Individualized Diet? If you’ve been struggling to lose weight and keep it off - it could be your gut microbiome. While Viome doesn’t guarantee weight loss, it has been an exciting result many of our customers have reported. &amp;quot;Fiona’s update day 37!&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;We know weight loss can be tough. Find out if your weight struggles are due to a gut microbiome imbalance with Viome - and let’s tip the scales in your favor. Your gut microbes actually digest much of your food for you. When your gut microbiota help digest your food, they turn it into nutrients, neurotransmitters, vitamins, hormones, and more. Through these metabolites, the composition of your gut microbiome influences nearly every metabolic activity. It’s accurate to think of your gut microbiome as an organ that’s part immune system and part energy regulator. If your gut microbiome is imbalanced, certain bacteria end up working to protect themselves from the harsh environment and are not able to help you. In the worst case scenario, you can have microbiota adding to your health problems, making it harder for you to get healthy and lose weight. Viome’s metatranscriptomic technology has allowed us identify microbial pathways and functions, specifically those that influence weight loss or gain.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Want to dig deeper? Here are 3 major mechanisms that affect weight loss or gain through different microbial pathways. Butyrate - Butyrate helps combat obesity through increasing satiety (feeling of fullness), and reducing overall inflammation. Low grade inflammation is a big contributor to weight gain. Propionate - Similar to butyrate, propionate also helps fight weight gain through stimulating satiety and reducing inflammation. Acetate - Acetate is responsible for modulating the production of insulin. Higher insulin levels increase fat storage and prevent the body from releasing it for energy production. Acetate made by microbes actually signals the brain to make more insulin, leading to weight gain. Each of these are created from many different substrates (elements found in your food) and play a critical role in regulating your weight. What the microbes are making them from (ie. Viome’s recommendations are aimed at influencing the production of these various short chain fatty acids through supplying the right food and supplements. Your recommendations are based on what your microbes are currently doing and what can be done to shift them to function better.&amp;lt;br&amp;gt;&lt;/div&gt;</summary>
		<author><name>Mildred36T</name></author>
		
	</entry>
	<entry>
		<id>https://crianzamutua.mx/index.php?title=Usuario:Mildred36T&amp;diff=49156</id>
		<title>Usuario:Mildred36T</title>
		<link rel="alternate" type="text/html" href="https://crianzamutua.mx/index.php?title=Usuario:Mildred36T&amp;diff=49156"/>
		<updated>2026-08-13T18:13:22Z</updated>

		<summary type="html">&lt;p&gt;Mildred36T: Página creada con «Hello from United Kingdom. I'm glad to came here. My first name is Alexandria. &amp;lt;br&amp;gt;I live in a city called Portscatho in western United Kingdom.&amp;lt;br&amp;gt;I was also born in Ports…»&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;Hello from United Kingdom. I'm glad to came here. My first name is Alexandria. &amp;lt;br&amp;gt;I live in a city called Portscatho in western United Kingdom.&amp;lt;br&amp;gt;I was also born in Portscatho 37 years ago. Married in November year 2005. I'm working at the backery.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Also visit my web blog; [http://www.tangjia7.com:8901/estellapritcha MedicGLP Website]&lt;/div&gt;</summary>
		<author><name>Mildred36T</name></author>
		
	</entry>
</feed>